M&A | Partnerships

The new company will manage a portion of Seikagaku's pharmaceutical and medical device development in North America.

OrthoPediatrics will distribute CERAMENT bone void filler to pediatric hospitals within the United States.

OrthogenRx has developed GenVisc and TriVisc viscosupplementation products to treat OA knee pain.

NuVasive Specialized Orthopedics will supply the STIMULAN orthobiologic calcium matrix in Germany.

Link Health will have global rights for development, manufacturing and commercialization of ALLOB allogeneic bone cell therapy.

Biologics4Life is developing a injectable synthetic bone graft materials, complementing Graftys' resorbable calcium phosphate cement.

The combined company will operate as a pure-play regenerative medicine and orthopedics company, serving hospital, ASC and office care settings.

Vilex will market and distribute Royal Biologics' portfolio of Autologous and Live Cellular therapies for lower extremity orthopedic procedures.

The merger will create a company positioned with products and specialized salesforces serving hospital, ambulatory surgical center and office care settings.

Exactech's Optecure demineralized bone matrix will complement RTI Surgical's portfolio of bone graft substitutes.